Neurology
Found 5 results
Filters: Keyword is Disability Evaluation  [Clear All Filters]
2018
Kocsik AS, Klein DE, Liedke M, Kaunzner UW, Nealon NM, Gauthier SA, Vartanian T, Perumal JS.  2018.  Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.. J Neurol. 265(5):1226-1229.
2017
Murthy SB, Awad I, Harnof S, Aldrich F, Harrigan M, Jallo J, Caron J-L, Huang J, Camarata P, Lara LRivera et al..  2017.  Permanent CSF shunting after intraventricular hemorrhage in the CLEAR III trial.. Neurology. 89(4):355-362.
2016
Murthy SB, Urday S, Beslow LA, Dawson J, Lees K, W Kimberly T, Iadecola C, Kamel H, Hanley DF, Sheth KN et al..  2016.  Rate of perihaematomal oedema expansion is associated with poor clinical outcomes in intracerebral haemorrhage.. J Neurol Neurosurg Psychiatry. 87(11):1169-1173.
Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D et al..  2016.  Relapses in multiple sclerosis: Relationship to disability.. Mult Scler Relat Disord. 6:10-20.
2012
Perumal JS, Foo F, Cook P, Khan O.  2012.  Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.. Mult Scler. 18(8):1197-9.